Gemini Therapeutics

📍 Cambridge, United States🗓 Founded 2015👥 38 employees💰 Last funded 2016
Biotechnology🌐 geminitherapeutics.com
Website LinkedIn
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics. For more information, visit www.GeminiTherapeutics.com.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Gemini Therapeutics?
Gemini Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Gemini Therapeutics last raise funding?
The most recent investment in Gemini Therapeutics recorded on gritt.io was in 2016.
When was Gemini Therapeutics founded?
Gemini Therapeutics was founded in 2015.
What industry is Gemini Therapeutics in?
Gemini Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Gemini Therapeutics based?
Gemini Therapeutics is headquartered in Cambridge, United States.